Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation

Ann Oncol. 2017 Apr 1;28(4):904-905. doi: 10.1093/annonc/mdx007.

Authors

J Schrader¹, F O Henes², D Perez³, S Burdak-Rothkamm⁴, A Stein⁵, J R Izbicki³, A W Lohse¹

Affiliations

¹ Departments of Gastroenterology and Hepatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
² Interventional and Diagnostic Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
³ General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁴ Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
⁵ Department of Oncology and Hematology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

PMID: 28327903
DOI: 10.1093/annonc/mdx007

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Antineoplastic Agents / therapeutic use
Everolimus / therapeutic use*
Germ-Line Mutation*
Humans
Immunohistochemistry
Neoplasm Metastasis
Neoplasm Staging
Neuroendocrine Tumors / drug therapy*
Neuroendocrine Tumors / enzymology
Neuroendocrine Tumors / genetics*
Neuroendocrine Tumors / pathology
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / enzymology
Pancreatic Neoplasms / genetics*
Pancreatic Neoplasms / pathology
TOR Serine-Threonine Kinases / antagonists & inhibitors*
Tuberous Sclerosis Complex 2 Protein
Tumor Suppressor Proteins / genetics*

Substances

Antineoplastic Agents
TSC2 protein, human
Tuberous Sclerosis Complex 2 Protein
Tumor Suppressor Proteins
Everolimus
MTOR protein, human
TOR Serine-Threonine Kinases